OBJECTIVE: To determine any possible adverse effect of 1-deamino 8-D-arginine vasopressin (DDAVP) spray on nasal cytology and mucociliary clearance in patients with nocturnal enuresis. METHODS: Twenty-two children aged 6-16 enrolled in the study. Epithelial surface cells samples were taken from the nasal mucosa and mucociliary clearance time was calculated before and 1 and 6 months after administration of DDAVP spray. RESULTS: No qualitative changes in the epithelial surface cells and mucociliary clearance time were observed at 1 and 6 months after therapy. CONCLUSION: Based on the findings of the present study, DDAVP spray can be used for 6 months in children without apparent risk of damage to the epithelial surface cells and mucociliary clearance time.
OBJECTIVE: To determine any possible adverse effect of 1-deamino 8-D-arginine vasopressin (DDAVP) spray on nasal cytology and mucociliary clearance in patients with nocturnal enuresis. METHODS: Twenty-two children aged 6-16 enrolled in the study. Epithelial surface cells samples were taken from the nasal mucosa and mucociliary clearance time was calculated before and 1 and 6 months after administration of DDAVP spray. RESULTS: No qualitative changes in the epithelial surface cells and mucociliary clearance time were observed at 1 and 6 months after therapy. CONCLUSION: Based on the findings of the present study, DDAVP spray can be used for 6 months in children without apparent risk of damage to the epithelial surface cells and mucociliary clearance time.